Literature DB >> 21859897

Treatment of thyroid cancer with the new oral agents.

J C Galofré, J M Gómez-Sáez, C A Escola, E Anda, A Calleja, S Donnay, A Lucas-Martin, E Menéndez-Torre, V Pereg, B Pérez-Corral, J Santamaría, G Riesco-Eizaguirre, C Zafon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21859897     DOI： 10.1093/annonc/mdr409

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Should the prescription of oral anticancer drugs be restricted?

Authors:  Alfredo Ramos; José Lopez Torrecilla; Pedro Lara; Ismael Herruzo; Jorge Contreras; Ana Mañas; Ferran Guedea
Journal:  Rep Pract Oncol Radiother       Date:  2012-07-19

2.  The prescription of oral anticancer drugs: Another perspective.

Authors:  Luis Linares; Adela Poitevin; Cuauhtemoc De la Pena; Keith R Britton; Rosalba Ospino; Raul Lara; Gustavo Sarria; Neiro Motta; Nicholas Rene; Luis Pinillos; Paulo Novaes
Journal:  Rep Pract Oncol Radiother       Date:  2012-11-08

3.  Comments to SEOM clinical guidelines for the treatment of thyroid cancer.

Authors:  Garcilaso Riesco-Eizaguirre; Juan Carlos Galofré; Carlos Zafón; Cristina Alvarez-Escolá; Emma Anda; Amparo Calleja; Sergio Donnay; Anna Lucas-Martín; Edelmiro Menéndez-Torre; Vicente Pereg; Begoña Pérez-Corral; Javier Santamaría; Jose Manuel Gómez-Sáez
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.